Navigation Links
Weight-Loss Drug Meridia Pulled From U.S. Market

By Steven Reinberg
HealthDay Reporter

FRIDAY, Oct. 8 (HealthDay News) -- The obesity drug Meridia has been withdrawn from the U.S. market because of an increased risk of heart attack and stroke, federal health officials said Friday.

Pharmaceutical giant Abbott Laboratories voluntarily agreed to pull the drug after a U.S. Food and Drug Administration review of data that showed a 16 percent increased risk for heart attack, stroke and death among people taking Meridia (sibutramine), compared with those taking a placebo.

Earlier Friday, Health Canada, the nation's health department, said Abbott would voluntarily pull the drug from the market there.

"FDA requested this withdrawal after concluding that the continued availability of this product is not justified since patients taking the drug are at an increased risk of suffering a heart attack or stroke," Dr. John Jenkins, director of the Office of New Drugs in FDA's Center for Drug Evaluation and Research, said during an afternoon news conference.

Besides finding an increased risk of heart attack and stroke, the review trial, called the Sibutramine Cardiovascular Outcomes Trial (SCOUT), found only a small difference in weight loss among those taking the drug and those receiving a placebo, agency officials said.

"Physicians are advised to stop prescribing Meridia to their patients, pharmacists are advised to stop dispensing Meridia, and patients are advised to stop taking this drug and dispose of any remaining product," Jenkins said.

Jenkins advised those taking Meridia, which is a stimulant, to discuss with their doctor other ways to lose weight.

Currently, about 100,000 people in the United States take Meridia, Dr. Gerald Dal Pan, director of FDA's Office of Surveillance and Epidemiology, noted at the news briefing.

In a news release, Abbott said the company "believes sibutramine has a positive risk/benefit profile in the approved patient population, but will comply with the FDA's request."

The FDA approved Meridia in November 1997 for weight loss and maintenance of weight loss in obese people, and in overweight people with other risks for heart disease.

The agency's approval was based on studies showing that about twice as many people taking Meridia lost at least 5 percent of their body weight compared with people taking a placebo who used diet and exercise alone to lose weight, Jenkins said.

Jenkins said that, when the drug was approved, the FDA did have safety concerns because Meridia was known to increase both blood pressure and heart rate. However, the FDA believed at the time that the benefit of losing weight outweighed the risk of increased blood pressure and heart rate, he said.

The European Medicines Agency required Abbott to undertake the post-approval SCOUT trial, and in January that agency banned all anti-obesity drugs containing sibutramine.

In a related moved Friday, the FDA also warned consumers about another weight-loss drug, Slimming Beauty Bitter Orange Slimming Capsules, which contains the same active ingredient as Meridia -- sibutramine.

The capsules can cause the same cardiovascular problems as Meridia, the FDA said. Slimming Beauty is sold over the Internet by Beautiful Health Inc.

More information

For more on the Slimming Beauty recall, visit the U.S. Food and Drug Administration.

SOURCES: Oct. 8, 2010, teleconference with John Jenkins, M.D., director, Office of New Drugs, Center for Drug Evaluation and Research, and Gerald Dal Pan, M.D., M.H.S., director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, both U.S. Food and Drug Administration

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Repeated Weight-Loss Surgery Carries Added Risks
2. Kirstie Alley Launches Organic Weight-Loss System Organic Liaison
3. 28-Year Old from Texas Discovers His Own 'Instant Weight-Loss' Miracle Online
4. Weight-Loss Surgery May Ease Childbirth Risks
5. Study Finds Patients Breathe Easier After Weight-Loss Surgery
6. Houston Weight-Loss Surgical Specialists Offer Gastric Sleeve Operation For $11K
7. Rare Cases of Liver Damage Tied to Weight-Loss Drug
8. Body-image distortion predicts onset of unsafe weight-loss behaviors
9. Complications From Weight-Loss Surgery Relatively Low
10. Weight-Loss Surgery May Cut Type 2 Diabetes Medication Use
11. Weight-Loss Surgery for Teens May Be Gaining Advocates
Post Your Comments:
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... N.C. , Nov. 25, 2015 ... the planned investment of at least $15.8  Million ... Wilmington, NC . The expansion ... capacity to meet the growing demands of the ... site expansion will provide up to ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
Breaking Medicine Technology: